Know Cancer

forgot password

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

Not Enrolling

Thank you

Trial Information

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)


Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also
co-infected with HCV. Thus, hemophiliacs represent an important population for studies of
the natural history of these chronic viral infections.

Moreover, the high rate of co-infection makes it an ideal group for assessing the
interaction between the viruses and the relationship between viral specific immune responses
and clinical progression.

Although the hemophiliac poulation is unique, co-infection by these chronic viral pathogens
is becoming increasingly common, particularly amongst intravenous drug users, who account
for approximately 25% of the HIV-1 epidemic in the United States.


The aim of this study is to determine if polymorphism in the promoter region of TH1 and Th2
cytokines are associated with (1) intracellular cytokines levels in CD4 + Tcells, (2) Human
Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) viral loads, and (3) clinical
progression of HIV1 to AIDS in hemophiliacs.


The current proposal will investigate host genetic factors related to HIV-1 and HCV
immunopathogenesis by studying children and adolescents enrolled in the Hemophilia Growth
and Development Study (HGDS).


This study is in collaboration with the principle investigators of the Hemophilia Growth and
Development Study (HGDS) as part of a grant "Pathogenesis of HIV and HCV in Hemophilia:
HGDS-3" with funding support by NIH/NICHD for the period 9/25/01 through 8/31/2005.

This multicenter, United States study represents a well-characterized, prospectively
followed cohort of HCV-infected hemophiliacs, of whom 207 are HIV-1 co-infected.

Enrollment of the hemophiliac cohort was completed between 3/89 and 6/90. The final
observation of the cohort (follow-up 16) was concluded during 7/98. No new samples or
clinical data will be collected on this population.

The LGD plays two roles in this project: (1) an administrative role overseeing the
withdrawal, handling, and transport of samples from the HGDS/LGD and central repositories at
the NCI-Frederick, and (2) a scientific role continuing investigations to determine the role
of host genetic factors in Th1 and Th2 immune response and regulation of HCV and HIV viral

Inclusion Criteria


The current Study will involve analysis of existing samples (DNA, serum, cells, plasma)
and data. The entire set of 333 subjects in the HGDS cohort will be analyzed.


No subjects will be excluded from the HGDS cohort.

Type of Study:


Study Design:


Principal Investigator

Michael Dean, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

March 2002

Completion Date:

Related Keywords:

  • Hemophilia
  • Genotyping
  • Polymorphisms
  • Co-Infection
  • Chemokines
  • Associations
  • HIV
  • HCV
  • Hepatitis C
  • Hemophilia
  • Hemophilia A



University of Iowa Iowa City, Iowa  52242
University of Oklahoma Oklahoma City, Oklahoma  73190
Wayne State University Hutzel Hospital Detroit, Michigan  48201
University of California, San Diego La Jolla, California  92037-1709
NCI Frederick Cancer Research Center Frederick, Maryland  21702-1201
University of Nebraska Omaha, Nebraska  68198
Mt. Sinai Medical Center New York, New York  10029
Cornell University New York, New York  10021
Childrens Hospital, Los Angeles Los Angeles, California  90054-0700
St. Vincent Hospital & Health Care Center Indianapolis, Indiana  46260
Tulane University New Orleans, Louisiana  70112-2699
Childrens Mercy Hospital Kansas City, Missouri  
Milton Hershey Medical Center Hershey, Pennsylvania  17033-2390
University of Texas, Houston Houston, Texas  77225
University of Texas, San Antonio San Antonio, Texas  78229-3900